Therefore, based on their findings, they recommend a comprehensive eye exam for patients living with MG who experience vision ...
Insights from AANEM 2025, including anticipated presentations, key takeaways, and how emerging research in myasthenia gravis ...
Dr Katherine Ruzhansky previews presentations on biomarkers, new therapies, and translational science at AANEM 2025.
Regeneron could be just a few months away from filing for approval of a therapy for the neuromuscular disorder generalised myasthenia gravis (gMG), cemdisiran, which can be dosed just four times a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback